Monte Rosa Therapeutics Cash Flow Statement
NASDAQ: GLUEHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Monte Rosa Therapeutics free cash flow
In fiscal 2025, Monte Rosa Therapeutics generated -$22.8 million of operating cash flow and spent $4.7 million on capital expenditures. That left free cash flow of -$27.5 million, a free-cash-flow margin of -22.2% of revenue. Free cash flow was down 172.3% from the prior year's $38.0 million.
Summary generated from market data by MetaCap's automated system. Methodology
Monte Rosa Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Net Income | -38.63M | -72.70M | -135.35M | -108.50M | -73.96M | -35.88M |
| Net Income growth (YoY) | — | — | — | — | — | — |
| Depreciation & Amortization | 8.36M | 8.12M | 6.22M | 3.75M | 2.13M | 537.00K |
| Stock-Based Compensation | 18.86M | 18.13M | 16.67M | 11.66M | 5.20M | 354.00K |
| Change in Working Capital | -5.58M | 88.04M | 56.84M | -2.87M | -6.71M | 2.06M |
| Operating Cash Flow | -22.80M | 42.00M | -43.80M | -92.47M | -59.36M | -23.05M |
| Capital Expenditures | -4.70M | -3.99M | -19.04M | -12.91M | -9.73M | -3.39M |
| Investing Cash Flow | -101.83M | -44.45M | 88.80M | -219.22M | -9.65M | -3.39M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | — |
| Financing Cash Flow | 30.35M | 98.89M | 27.49M | 20.47M | 377.56M | 60.06M |
| Net Change in Cash | -94.28M | 96.44M | 72.49M | -291.22M | 308.55M | 33.62M |
| Free Cash Flow | -27.50M | 38.01M | -62.84M | -105.38M | -69.09M | -26.44M |
This table shows 6 annual periods of Monte Rosa Therapeutics's cash flow statement, from FY 2025 back to FY 2020, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow GLUE's reporting calendar. What is a cash flow statement?